Evidence review
Has BPC-157 ever been tested in a human clinical trial?
The answer
No. Searching the National Library of Medicine's index across three name variants in August 2026 returned 228 papers mentioning the compound and none indexed under the clinical-trial publication type.
The claim that a compound has never been tested in people is a measurement, and it is worth only as much as the search behind it. The search this index recorded ran across three spellings the literature actually uses — "BPC 157" and "BPC-157", "pentadecapeptide BPC", and "body protection compound" — with a deliberately invalid identifier included in the same run to confirm the instrument was answering rather than failing silently.
It returned 228 records mentioning the compound and zero under the clinical-trial publication type [2]. The denominator is the point: this is not a compound nobody has written about. It is a compound with a substantial published literature, none of which is a trial in human beings.
A reader can repeat the search; the reference below carries the query rather than a description of it. That is the standard this index holds itself to, and it is the standard a claim of absence anywhere else should be held to as well.
The 228 papers are not empty. They describe a synthetic pentadecapeptide corresponding to a fragment of Body Protection Compound, a protein identified in human gastric juice, and they attribute its effects principally to promotion of angiogenesis and to modulation of growth-factor signaling [1]. The models are rodent models of tendon transection, ligament injury, and gastrointestinal damage [1].
Those mechanisms are described in animals and have not been established in humans [1]. That sentence is doing real work: a mechanism observed in a rat is a hypothesis about a person, and the step that converts one into the other is the step this record does not contain. No product containing BPC-157 has completed the clinical development that an approval requires [1].
The absence is not merely an academic observation; it is the substance of the agency's position. In September 2023 the FDA placed BPC-157 in Category 2 of its interim bulk drug substances list, the category reserved for substances with significant safety concerns, citing immunogenicity risk and impurity questions, and that placement barred licensed pharmacies from compounding it [3].
In April 2026 the agency removed BPC-157 and eleven other peptides from Category 2 without adding them to Category 1; the removal ended an explicit prohibition and conferred no authorization. In July 2026 the Pharmacy Compounding Advisory Committee voted 8–6 to recommend adding the compound to the section 503A bulks list [4]. That vote is advisory, the FDA has issued no final rule, and no licensed United States pharmacy may lawfully compound BPC-157 today. The dated ledger is on the monograph; the arithmetic of the whole meeting is in the vote ledger.
BPC-157 draws roughly 183,000 United States searches per month while its human trial record remains empty. That gap between commercial visibility and published evidence is unusually wide even in this market, and it is worth naming plainly: a reader weighing this compound is weighing animal data.
The material offered for sale compounds the problem. Because no lawful compounding route exists, what is sold under the name is research-use-only chemical supply, produced and sold outside pharmacy licensure, prescriber oversight, and pharmaceutical quality standards; its identity, purity, and sterility are whatever the vendor says they are. The research-only page sets out why removal from a prohibition list is not permission, and the glossary defines what the labeling posture does and does not mean.
Monographs
Reference tables
Every source below is inherited from a monograph in this index, where it was verified at writing time; this review introduces none of its own. The pointer beside each entry names the monograph and the reference number it came from.